非布司他联合前列地尔对慢性肾脏病患者肾功能及血尿酸eGFR的影响

Effects of Febuxostat Combined with Alprostadil on Renal Function Serum Uric Acid and EGFR in Patients with Chronic Kidney Disease

目的:探讨非布司他联合前列地尔对慢性肾脏病患者肾功能及血尿酸、肾小球滤过率(eGFR)的影响。方法:选择2018年1月至2021年1月在我院接受治疗的103例慢性肾脏病患者,采用简单随机分组法分为联合组(n=52)和单药组(n=51)。单药组给前列地尔治疗,联合组在单药组的基础上联合非布司他治疗。比较两组临床疗效、血尿酸、eGFR、血肌酐(Scr)、尿素氮(BUN)、24h尿蛋白定量、及不良反应发生情况。结果:治疗后,两组总有效率比较差异有统计学意义(P<0.05);治疗前,联合组和单药组肾功能比较差异无统计学意义;治疗后,联合组和单药组Scr、BUN、24h尿蛋白定量明显降低,且联合组低于单药组,两组治疗前后差值比较差异有统计学意义(P<0.05);治疗前,联合组和单药组血尿酸、eGFR比较差异无统计学意义;治疗后,联合组和单药组血尿酸明显降低,且联合组低于单药组,eGFR明显升高,且联合组高于单药组,两组治疗前后差值比较差异有统计学意义(P<0.05);两组不良反应总发生率为5.77%、15.69%,差异无统计学意义(P>0.05)。结论:在慢性肾脏病患者中应用非布司他联合前列地尔治疗疗效显著,可有效改善患者肾功能及血尿酸、eGFR水平。

Objective:To study the effects of febuxostat combined with alprostadil on renal function,serum uric acid and Gglomerular filtration rate(eGFR)in patients with chronic kidney disease.Methods:A total of 103 patients with chronic kidney disease who received treatment in our hospital from January 2018 to January 2021 were selected and divided into combination group(n=52)and monotherapy group(n=51)by simple random grouping method.The monotherapy group was treated with alprostadil,and the combination group was treated with febuxostat on the basis of the monotherapy group.The clinical efficacy,serum uric acid,eGFR,serum creatinine(Scr),urea nitrogen(BUN),24-hour urine protein level and the incidence of adverse reactions were compared between the two groups.Results:After treatment,there was statistical difference in the total effective rate between the two groups(P<0.05).Before treatment,there was no significant difference in renal function between the combination group and the monotherapy group.After treatment,Scr,BUN and 24-hour urine protein quantification were significantly decreased in both groups,and the combination group was lower than the monotherapy group;the difference was statistically significant(P<0.05).Before treatment,there was no significant difference in serum uric acid and eGFR between the two groups.After treatment,serum uric acid was significantly decreased in both groups,and eGFR was significantly increased in the combination group compared with the monotherapy group,with statistical significance(P<0.05).The total incidence of adverse reactions between the two groups was 5.77%and 15.69%,with no statistical significance(P>0.05).Conclusion:In patients with chronic kidney disease,febuxostat combined with aprostadil has a significant therapeutic effect,which can effectively improve the renal function and serum uric acid and eGFR levels.